Skip to main content
Premium Trial:

Request an Annual Quote

$4 Million and Years of Hype

According to SEC filings, 23andMe gave $4 million to one executive officer, blogs BNET's Rachel Lehmann-Haupt. That money was payment to a company officer for a loan, but Lehmann-Haupt notes that "given the fact that it’s a rocky time financially for 23andMe, it also seems like a bad time to lay out so much cash to one person." Indeed, in the past year, Linda Avey left, the company had a round of layoffs, and increased the price of their products. Razib at Gene Expression adds that some 23andMe employees are not happy, according to postings at Glassdoor. There, one employee wrote that "all decisions came down to one person, and it was NOT the ceo. Senior managers made some grave mistakes and many employees suffered." Daniel MacArthur at Genetic Future says that "personal genomics is transparently going through the Gartner hype cycle … and right now we're firmly wedged in the trough of disillusionment, following a peak of inflated expectations for which personal genomics companies themselves must take the bulk of the blame."

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.